Hospital
Barbara Ann Karmanos Cancer Hospital
Barbara Ann Karmanos Cancer Hospital was paid $42.45M by Medicaid between Jan 2018 and Dec 2024, across 236 billing codes. Its largest line is J9271, Injection, pembrolizumab, 1 mg — 31% of everything it billed.
33Billing provider infoBARBARA ANN KARMANOS CANCER HOSPITAL
DETROIT, MI 48201
DETROIT, MI 48201
33aNPI1316900277assigned 04/10/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$42.45M
24GClaims547,347
24DCodes billed236
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#29 of 86
Median peer was paid$21.55M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 74,359 | $7.79M | |
| 2019 | 80,196 | $5.84M | |
| 2020 | 72,046 | $5.22M | |
| 2021 | 79,360 | $5.62M | |
| 2022 | 78,158 | $5.64M | |
| 2023 | 91,381 | $6.45M | |
| 2024incomplete | 71,847 | $5.88M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 31% | 2,263 | 1,801 | $13.36M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 11% | 69,653 | 52,644 | $4.46M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 6.7% | 17,319 | 10,400 | $2.86M |
| 77386 | 4.7% | 7,228 | 648 | $1.98M | |
| 78815 | Positron emission tomography (PET) for limited area imaging | 4.5% | 2,493 | 2,473 | $1.92M |
| J9299 | Injection, nivolumab, 1 mg | 4.2% | 370 | 259 | $1.79M |
| 77412 | 3.5% | 12,115 | 1,370 | $1.49M | |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | 2.7% | 560 | 329 | $1.13M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 2.1% | 18,672 | 18,601 | $912K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.1% | 4,881 | 4,824 | $881K |
| J2505 | Injection, pegfilgrastim, 6 mg | 1.9% | 374 | 296 | $826K |
| 19083 | 1.8% | 1,013 | 985 | $774K |
224 more codes
| 77334 | 1.6% | 2,140 | $663K | |
| J9035 | Injection, bevacizumab, 10 mg | 1.5% | 290 | $645K |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 1.4% | 313 | $608K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 12,299 | $491K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 6,266 | $394K |
| 77336 | <1% | 5,490 | $359K | |
| 77300 | <1% | 1,615 | $314K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 532 | $270K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,376 | $269K |
| 77295 | <1% | 429 | $247K | |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 345 | $236K |
| 36512 | <1% | 400 | $235K | |
| 96417 | <1% | 5,852 | $227K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,600 | $222K |
| 70491 | <1% | 1,535 | $212K | |
| Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | <1% | 129 | $198K |
| 76642 | <1% | 7,101 | $196K | |
| 77066 | Tomosynthesis, mammo | <1% | 3,266 | $191K |
| J9070 | Cyclophosphamide, 100 mg | <1% | 906 | $189K |
| 36430 | <1% | 1,002 | $188K | |
| 77065 | Tomosynthesis, mammo | <1% | 3,890 | $173K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 1,253 | $155K |
| 31575 | <1% | 1,886 | $148K | |
| 96415 | <1% | 2,853 | $140K | |
| 80053 | Comprehensive metabolic panel | <1% | 35,178 | $140K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,549 | $136K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 120 | $131K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,821 | $127K |
| 96416 | <1% | 841 | $124K | |
| 96367 | <1% | 3,425 | $122K | |
| 78306 | <1% | 647 | $122K | |
| 36556 | <1% | 259 | $121K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 8,584 | $119K |
| J1950 | Injection, leuprolide acetate (for depot suspension), per 3.75 mg | <1% | 123 | $117K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 38,105 | $112K |
| 77290 | <1% | 550 | $89K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 884 | $88K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,507 | $78K |
| 36561 | <1% | 57 | $73K | |
| 77338 | <1% | 392 | $68K | |
| 96411 | <1% | 1,700 | $65K | |
| 72197 | <1% | 216 | $58K | |
| 77301 | <1% | 85 | $56K | |
| 88307 | <1% | 396 | $55K | |
| 77385 | <1% | 237 | $55K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 41 | $53K |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 148 | $49K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,311 | $48K |
| J9306 | Injection, pertuzumab, 1 mg | <1% | 22 | $48K |
| 88341 | <1% | 759 | $47K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,588 | $45K |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | <1% | 51 | $43K |
| Q3014 | Telehealth originating site facility fee | <1% | 2,422 | $39K |
| 71250 | <1% | 641 | $36K | |
| 96402 | <1% | 2,062 | $35K | |
| 83735 | <1% | 11,346 | $30K | |
| 78816 | <1% | 37 | $29K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 516 | $26K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,132 | $24K |
| 86300 | <1% | 3,004 | $24K | |
| 82784 | <1% | 3,110 | $22K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 553 | $20K |
| 88342 | <1% | 815 | $20K | |
| 77280 | <1% | 282 | $19K | |
| 83615 | <1% | 8,396 | $19K | |
| 86900 | <1% | 5,177 | $18K | |
| 82378 | <1% | 2,199 | $16K | |
| 84153 | <1% | 2,276 | $16K | |
| 86850 | <1% | 4,850 | $16K | |
| 83521 | <1% | 1,129 | $15K | |
| 86334 | <1% | 1,672 | $14K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 294 | $14K |
| J9045 | Injection, carboplatin, 50 mg | <1% | 2,209 | $14K |
| 86304 | <1% | 1,345 | $12K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,188 | $10K |
| 76536 | <1% | 256 | $10K | |
| J9171 | Injection, docetaxel, 1 mg | <1% | 271 | $9K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 281 | $9K |
| 84165 | <1% | 1,985 | $9K | |
| 38505 | <1% | 12 | $8K | |
| C8908 | Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral | <1% | 41 | $8K |
| 84439 | <1% | 2,005 | $8K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,555 | $7K |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 2,636 | $7K |
| 76641 | <1% | 276 | $7K | |
| 96409 | <1% | 73 | $7K | |
| 87496 | <1% | 582 | $6K | |
| 82728 | <1% | 1,014 | $6K | |
| 82565 | <1% | 3,022 | $6K | |
| 84100 | <1% | 2,722 | $6K | |
| 84703 | <1% | 1,747 | $5K | |
| 86901 | <1% | 5,175 | $5K | |
| C9463 | Injection, aprepitant, 1 mg | <1% | 45 | $5K |
| 84403 | <1% | 474 | $5K | |
| 86301 | <1% | 570 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 350 | $5K |
| 74183 | <1% | 39 | $5K | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 395 | $5K |
| 85610 | <1% | 2,789 | $4K | |
| 77080 | <1% | 77 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,137 | $3K |
| G0378 | Hospital observation service, per hour | <1% | 257 | $3K |
| 94726 | <1% | 129 | $3K | |
| 82607 | <1% | 390 | $3K | |
| 83540 | <1% | 462 | $3K | |
| 85730 | <1% | 1,358 | $3K | |
| 96401 | <1% | 172 | $3K | |
| 78472 | <1% | 16 | $3K | |
| J1750 | Injection, iron dextran, 50 mg | <1% | 21 | $3K |
| 84702 | <1% | 334 | $2K | |
| 84550 | <1% | 1,031 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,781 | $2K |
| 85027 | <1% | 932 | $2K | |
| 86923 | <1% | 212 | $2K | |
| 86769 | <1% | 57 | $1K | |
| 94060 | <1% | 14 | $1K | |
| 85046 | <1% | 508 | $1K | |
| 81001 | <1% | 1,021 | $1K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 108 | $1K |
| J9000 | Injection, doxorubicin hydrochloride, 10 mg | <1% | 303 | $1K |
| 82746 | <1% | 147 | $1K | |
| 90671 | <1% | 12 | $933.94 | |
| 87305 | <1% | 322 | $885.07 | |
| 36591 | <1% | 63 | $830.30 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 12 | $780.68 |
| 76830 | Ultrasound, transvaginal | <1% | 12 | $780.68 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 12 | $776.82 |
| 87625 | <1% | 40 | $614.60 | |
| 74160 | <1% | 43 | $566.69 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 42 | $515.05 |
| 82533 | <1% | 50 | $505.54 | |
| 86800 | <1% | 61 | $487.72 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 340 | $468.35 |
| 82570 | <1% | 167 | $445.28 | |
| 94760 | <1% | 623 | $441.18 | |
| 86706 | <1% | 109 | $437.78 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 13 | $424.60 |
| 81003 | <1% | 401 | $356.94 | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 529 | $344.98 |
| 84432 | <1% | 26 | $225.39 | |
| 36592 | <1% | 41 | $194.37 | |
| 77062 | <1% | 1,576 | $190.40 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 12 | $183.73 |
| 84295 | <1% | 240 | $175.99 | |
| 84132 | <1% | 250 | $170.04 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 28 | $156.03 |
| 87799 | <1% | 17 | $150.04 | |
| 86140 | <1% | 72 | $143.43 | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,279 | $128.69 |
| 84481 | <1% | 12 | $100.27 | |
| 85014 | <1% | 274 | $99.03 | |
| 84156 | <1% | 59 | $97.22 | |
| J3490 | Unclassified drugs | <1% | 24,765 | $93.35 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 21 | $76.68 |
| 77061 | <1% | 899 | $74.10 | |
| 84166 | <1% | 12 | $72.69 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 7,324 | $71.71 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 4,915 | $50.14 |
| 96549 | <1% | 640 | $42.65 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,672 | $28.27 |
| 88142 | <1% | 79 | $24.14 | |
| 81025 | <1% | 17 | $22.56 | |
| 96368 | <1% | 1,110 | $21.69 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 6,724 | $8.63 |
| 82330 | <1% | 56 | $8.59 | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 557 | $8.31 |
| 87070 | <1% | 13 | $4.75 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,515 | $3.80 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,154 | $3.33 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 5,237 | $2.93 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 496 | $0.94 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 687 | $0.00 |
| C1752 | Catheter, hemodialysis/peritoneal, short-term | 0% | 231 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 2,510 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 307 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 3,797 | $0.00 |
| J9190 | Injection, fluorouracil, 500 mg | 0% | 971 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 7,264 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 1,252 | $0.00 |
| J0640 | Injection, leucovorin calcium, per 50 mg | 0% | 581 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 1,280 | $0.00 |
| S5000 | Prescription drug, generic | 0% | 1,808 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 541 | $0.00 |
| 76937 | 0% | 910 | $0.00 | |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 0% | 24 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 319 | $0.00 |
| 76942 | 0% | 27 | $0.00 | |
| 94729 | 0% | 131 | $0.00 | |
| 82542 | 0% | 105 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 12 | $0.00 |
| 90713 | 0% | 12 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 27 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 40 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 17 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 37 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 1,418 | $0.00 |
| C1769 | Guide wire | 0% | 788 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 2,923 | $0.00 |
| 77417 | 0% | 534 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 1,243 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 424 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 2,977 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 1,257 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 712 | $0.00 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 503 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 204 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 1,295 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 203 | $0.00 |
| 77001 | 0% | 354 | $0.00 | |
| C1892 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, peel-away | 0% | 108 | $0.00 |
| 83883 | 0% | 89 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 85 | $0.00 |
| J9074 | Injection, cyclophosphamide (sandoz), 5 mg | 0% | 18 | $0.00 |
| 36410 | 0% | 14 | $0.00 | |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | 0% | 362 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 27 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 13 | $0.00 |
| 96376 | 0% | 83 | $0.00 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 50 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 25 | $0.00 |
| J9202 | Goserelin acetate implant, per 3.6 mg | 0% | 12 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 16 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 22 | $0.00 |
| A9560 | Technetium tc-99m labeled red blood cells, diagnostic, per study dose, up to 30 millicuries | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOXTADER, REGINA (CFO)